Armitage R, Rush A J, Trivedi M, Cain J, Roffwarg H P
University of Texas Southwestern Medical Center, Dallas 75235-9070.
Neuropsychopharmacology. 1994 Apr;10(2):123-7. doi: 10.1038/npp.1994.14.
A polysomnographic study was conducted on 10 outpatients with major depression at baseline and during 4 to 8 weeks of open-trial treatment with nefazodone (400 to 600 mg/day). All 10 patients were treatment responders as evidenced by at least 50% reduction from baseline scores on the Hamilton Depression Rating Scale. Nefazodone was associated with significantly decreased wake and movement time and increased minutes and percentage of stage 2 sleep at the expense of light stage 1 sleep. Nefazodone did not increase rapid-eye-movement (REM) latency and it did not suppress REM sleep. In fact, a trend toward increased REM in the second REM period was observed, although decreased REM in the third REM period was also noted. In summary, nefazodone, an effective antidepressant, decreases arousals and wakefulness during sleep and reduces light non-REM sleep. This agent does not appear to suppress REM sleep or prolong REM latency in patients who respond to treatment.
对10名重度抑郁症门诊患者在基线期以及接受奈法唑酮（400至600毫克/天）开放试验治疗4至8周期间进行了多导睡眠图研究。所有10名患者均为治疗有效者，汉密尔顿抑郁量表评分较基线至少降低了50%。奈法唑酮与清醒和活动时间显著减少以及2期睡眠分钟数和百分比增加相关，代价是浅1期睡眠减少。奈法唑酮未增加快速眼动（REM）潜伏期，也未抑制REM睡眠。事实上，尽管在第三个REM期观察到REM减少，但在第二个REM期观察到REM有增加的趋势。总之，有效的抗抑郁药奈法唑酮可减少睡眠期间的觉醒和清醒，并减少浅非快速眼动睡眠。该药物似乎不会抑制接受治疗有反应患者的REM睡眠或延长REM潜伏期。
